Targeted expansion GeneXplain has a specialized bioinformatics platform and TRANSFAC suite with a strong presence in transcription factors, signaling networks, and genome-scale analyses. This combination presents opportunities to sell into biotech, pharma, and contract research organizations seeking integrated omics-to-therapy workflows.

Platform as value The Genome Enhancer and geneXplain platform offer end-to-end support for drug development from omics data to target identification. Leverage this to upsell premium analytics, training, and consulting services to customers pursuing precision medicine and target discovery programs.

Industry credibility A long-standing TRANSFAC heritage and periodic involvement in major conferences (for example FEBS Congress 2025) build credibility. Use this to approach research institutions and biotech buyers who prioritize established databases and validated workflows.

Mid-market focus With 11-50 employees and revenue in the mid-single to mid-range, geneXplain appears aligned with mid-market biotech and CROs. This suggests scalable, modular licensing, tiered access, and cost-effective onboarding as key sales angles.

Growth signals Recent product launches and historic updates indicate ongoing innovation and market adoption of Genome Enhancer. Target customers expanding multi-omics pipelines, bioinformatics staffing growth, and institutions investing in master regulator and TF information streams.